Project Grant R01DA059584
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $450,313 to evaluate the impact of psychotherapeutic advertising claims on cannabis purchasing behaviors among individuals with symptoms of depression and/or anxiety. The project aims to investigate the influence of psychotherapeutic advertising claims and mental health warning labels on online cannabis purchasing by simulating a...
- This $668,110 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and acceptability testing of a technology-based intervention to reduce cannabis misuse among college students. The project aims to refine an existing intervention that provides information on cannabis products, marketing, laws, and risks to increase young adults' cannabis literacy. The research will involve focus groups with...
- This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) to the Cambridge Public Health Commission, doing business as the Cambridge Health Alliance, will provide $177,110 to study the impact of cannabis legalization and commercialization on substance use and mental health outcomes among individuals with psychosis. The research will utilize quasi-experimental difference-in-difference methods to analyze data from the Population...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $159,139 Project Grant to George Washington University to research the "Impact of Derived Psychoactive Cannabis Product Marketing on Perceptions and Use Among Young Adults" under the Drug Use and Addiction Research Programs (CFDA 93.279). This grant, with a period of performance from August 15, 2025 to July 31, 2030, will support research focused on understanding and addressing cannabis...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $811,679 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of California, San Diego (UCSD) to investigate the effect of strengthened text-based warning labels on cannabis edible packaging. The research aims to assess a range of front-of-package warning label features, such as enlarged size, contrasting colors, prominent positioning, and rotating...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $395,995.00 to Oregon Health & Science University (OHSU) to conduct a 5-year mechanistic study on the reciprocal relationships between cannabis use, sleep, and the hypothalamic-pituitary-adrenal (HPA) axis. The study aims to determine the impact of sleep restriction or extension on cannabis use, and the impact of cannabis use on sleep...
- This federal Project Grant award of $686,692 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a study to assess the potential benefits of reduced cannabis consumption for adults with cannabis use disorder (CUD). The study will conduct an 8-week cannabis use reduction trial, where participants receive comprehensive CUD treatment including cognitive behavioral therapy, motivational interviewing, and incentives for...
- This federal Project Grant award of $3,227,517.00 was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to investigate the effects of full-spectrum cannabidiol (CBD) on alcohol consumption and alcohol use disorder phenotypes. The grant, awarded on September 20, 2025 with an ultimate completion date of August 31, 2029, aims to identify safe and novel medications for alcohol use disorders (AUD), which are a leading cause of...
- This four-year, $4.6 million project grant from the National Institute on Drug Abuse will fund research at the University of Miami exploring the linkage between cannabis use, route of administration, cannabinoid content, and measures of cardiovascular disease (CVD) risk in people living with HIV (PWH). Specifically, the principal investigator - an interventional cardiologist and physician scientist focused on HIV and CVD prevention - will collect comprehensive data on 300 PWH ages 18-60 to...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $162,259 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Rutgers, The State University of New Jersey. The project, titled "Effects and Equity Impacts of Cannabis Policy on Tobacco and Cannabis Co-Use in Young Adults," aims to determine the impact of evolving cannabis and cigar policies on blunt use, particularly among Black/African American young...
EFFECTS OF CANNABIS SPECIES LABELING AND MARKETING ON PERCEPTUAL, SUBJECTIVE AND OBJECTIVE USE OUTCOMES - PROJECT SUMMARY SALE OF CANNABIS FOR RECREATIONAL USE IS RAPIDLY BECOMING LEGAL ACROSS STATES IN THE US. WHILE CANNABIS USE POLICIES TYPICALLY CONTAIN MARKETING RESTRICTIONS, INCLUDING PROHIBITIONS ON MISLEADING MARKETING CLAIMS, THERE IS LIMITED RESEARCH TO INFORM OPERATIONALIZATION OF THESE POLICIES, AND THESE POLICIES ARE RARELY ENFORCED. CANNABIS PRODUCTS ARE OFTEN LABELED BASED ON "SPECIES" OR CULTIVAR (INDICA, SATIVA, OR HYBRID). NOTABLY, THERE IS LIMITED EVIDENCE THAT DIFFERENT SPECIES CONSISTENTLY HAVE DIFFERENT PROFILES OF CHEMICAL CONSTITUENTS. DESPITE THIS, CANNABIS IS MARKETED DIRECTLY TO CONSUMERS WITH PRODUCT LABELS "INDICA", "SATIVA", AND "HYBRID", AND WITH CORRESPONDING MARKETING CLAIMS THAT THE PRODUCT HAS SEDATIVE (E.G., RELAXATION, SLEEPINESS) OR ENERGIZING (E.G., FOCUS, PRODUCTIVITY, PHYSICAL ACTIVITY) EFFECTS. CONSUMERS ALSO REPORT EXPERIENCING SEDATIVE EFFECTS FROM INDICA- LABELED CANNABIS AND ENERGIZING EFFECTS FROM SATIVA-LABELED CANNABIS. THIS MAY TRANSLATE INTO UNSAFE USE: OUR PRIOR WORK HAS FOUND CONSUMERS ARE MORE LIKELY TO REPORT USING SATIVA-LABELED (VS. INDICA-LABELED) CANNABIS BEFORE DRIVING OR GOING TO WORK. DESPITE THE POTENTIAL FOR PUBLIC HEALTH HARM, THERE IS NO DATA DEMONSTRATING WHETHER PRODUCT PERCEPTIONS, USE EXPECTANCIES, AND SUBJECTIVE AND OBJECTIVE ACUTE EFFECTS OF USE VARY BY LABEL OR MARKETING CLAIM. RESEARCH FROM OTHER CONSUMER DOMAINS, INCLUDING TOBACCO, INDICATES THAT LABELING AND MARKETING CAN HAVE POWERFUL EFFECTS ON PRODUCT PERCEPTIONS, USE BEHAVIOR, AND USE EXPERIENCE. MARKETING AND LABELING FOR CANNABIS COULD SIMILARLY FOSTER INACCURATE PRODUCT PERCEPTIONS (E.G., REGARDING HARM), EXPECTANCY EFFECTS (E.G., ANTICIPATING A PRODUCT TO INCREASE FOCUS) AND LEAD TO UNSAFE USE (E.G., WHILE DRIVING). THIS UNDERMINES INITIATIVES TO PROMOTE SAFE USE OF CANNABIS AND RISKS PUBLIC HEALTH. TO DATE, CONTROLLED RESEARCH HAS NOT SYSTEMATICALLY EVALUATED HOW PRODUCT LABELING (INDICA, SATIVA, HYBRID) OR ASSOCIATED MARKETING CLAIMS (SEDATIVE VS. ENERGIZING) AFFECT USE BEHAVIOR, RISK PERCEPTION, OR ACUTE DRUG EFFECTS. THE PROPOSED RESEARCH USES A LARGE-SCALE CONTENT ANALYSIS OF CANNABIS LABELING AND MARKETING (AIM 1), A RANDOMIZED ONLINE EXPERIMENT (AIM 2), AND A PLACEBO-CONTROLLED RANDOMIZED LABORATORY EXPERIMENT (AIM 3) TO DOCUMENT THE SCOPE AND EFFECTS OF CANNABIS LABELING (INDICA, SATIVA, HYBRID) AND MARKETING CLAIMS (SEDATIVE, ENERGIZING). ULTIMATELY, THIS WORK WILL PROVIDE EVIDENCE TO INFORM CANNABIS MARKETING AND LABELING POLICIES, WHICH ARE NECESSARY TO PROTECT PUBLIC HEALTH.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $720.9k | 4/30/25 | ||
| Not listed | $689.1k | 7/1/24 | ||
| Not listed | $689.1k | 7/1/24 |